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Abstract
Background: In asthma, exacerbations and poor disease control are linked to airway allergic inflammation. Serum
periostin has been proposed as a systemic biomarker of eosinophilic inflammation. This pilot study aims at
evaluating whether in patients with moderate asthma, higher baseline levels of serum periostin are associated with
a greater risk of exacerbation.
Methods: Fifteen outpatients with moderate allergic asthma were recruited. Serum concentrations of periostin
were assessed (ELISA) at baseline, and the frequency of asthma exacerbations was recorded during a one-year
follow-up.
Results: Patients (M/F: 10/5, mean age of 47.6 ± 11.0 years) had mean ACQ score of 5.5 ± 4.2 and FEV1%pred of
81.9 ± 21.7 %. Baseline serum levels of periostin did not correlate with lung function parameters, nor with the ACQ
score (p ≥0.05 for all analyses). Five subjects (33 % of the study group) reported one or more exacerbations during
the following year. Baseline serum levels of periostin were significantly higher in subjects who experienced one or
more exacerbations during the one year period of follow-up, compared with subjects with no exacerbations:
median serum periostin level was 4047 ng/ml (range: 2231 to 4889 ng/ml) and 222 ng/ml (range 28.2 to
1631 ng/ml) respectively; p = 0.001.
Conclusion: The findings of the present pilot study could form the basis for the design of larger studies
aiming at developing strategies to identify asthmatic patients at risk for exacerbations.
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Background
The long-term goals in asthma management are the opti-
mal control of respiratory symptoms and the risk reduc-
tion of future exacerbations [1]. Exacerbations are linked
to the greater decline in lung function and to airway in-
flammation expressed by an increase of eosinophil count
in the sputum and of exhaled nitric oxide [2]. These
markers of eosinophilic inflammation are also related with
poor control of asthma [3]. Periostin proteins in periph-
eral blood correlate with airway eosinophilic inflamma-
tion, and have therefore the potential to be used as a
biomarker to select patients for asthma therapies targeting
TH2 inflammation [4]. In this regard, serum periostin has
been found to correlate with the increase of eosinophil
count in peripheral blood, in the induced sputum and
with asthma control in patients with severe and uncon-
trolled asthma [4]. Recently, Kenemitsu and colleagues [5]
found that higher serum levels of periostin were associ-
ated with greater decline in lung function in asthmatics.
Periostin has been used as a biomarker to predict the
response to TH2-target therapy with humanized mono-
clonal antibody to IL-13 (lebrikizumab) in uncontrolled
asthma patients: patients with high level of serum peri-
ostin at baseline showed a greater improvement with
lebrikizumab treatment, in comparison with patients
with low level of serum periostin [6]. The post-hoc ana-
lysis of the “Extra Study” [7] in uncontrolled severe
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asthmatics treated with omalizumab demonstrated a re-
duction in exacerbations by 30 % in patients with high
levels of periostin. These data support the hypothesis
that periostin could predict the response to treatment in
unstable patients with TH2 driven phenotype.
The aim of this study is to evaluate, in a pilot fashion,
whether patients with moderate asthma and higher base-
line levels of serum periostin show a greater risk of ex-
acerbation during a year of follow-up.
Methods
Subjects
Unselected consecutive individuals who fulfilled the
diagnostic criteria for asthma were enrolled [1]. Fifteen
asthmatics with moderate asthma were recruited at the
outpatient clinic for respiratory allergic diseases of the
University of Palermo, Italy. Current smoker patients, or
ex smokers defined as smoking at least ten pack-year, to-
gether with those affected by respiratory diseases other
than asthma were excluded from the study. To enter the
study, all subjects had to be under regular inhaled treat-
ment with beta-2 adrenergic long-acting bronchodilators
and corticosteroids (LABA/ICS in fixed combinations)
for a period of at least six months at the time of enroll-
ment. Patients were not different in terms of history of
exacerbations in the year before the enrollment. The
local Ethics Committee approved the protocol and writ-
ten informed consents were obtained.
Study design
The study had a duration of 52 weeks. After giving their
consent, all enrolled patients underwent an initial assess-
ment (Visit 1) during which clinical and lung functional
evaluations were performed. Peripheral blood was then
collected for the periostin concentration measurements.
All patients were then given the same LABA/ICS formu-
lation at the study entry and were followed for one year,
at three-month intervals. At each visit, compliance with
treatment was also assessed by the clinical investigators
by asking the patients to return the empty devices; the
correct use of the device was also assessed. Unscheduled
visits were allowed when symptoms worsened to identify
any exacerbation, which was treated with the use of oral
corticosteroids; the frequency of asthma exacerbations
was then recorded at three-month intervals. Salbutamol
as rescue medication, as well as anti-histamines during
exposure to allergens causing nasal and/or ocular symp-
toms, were allowed during the study period. No other
comorbid conditions or non respiratory medications
were present at the time of the study.
Clinical and functional assessments
Demographic and clinical data included age, sex, dur-
ation of disease, current treatment and the evaluation of
the atopic condition. The level of asthma control was
evaluated by the asthma control questionnaire (ACQ).
Exacerbation was defined as any acute worsening of re-
spiratory symptoms, such as shortness of breath, cough,
wheezing or chest tightness, which required changes in
treatment (i.e. use of oral corticosteroids), according to
the GINA guidelines [1]. Functional assessment included
measures of static and dynamic lung volumes, and was
performed using a fully computerized Stead-Wells
Water Seal Spirometer (Baires System; Biomedin; Padua,
Italy), using the helium dilution method. Measurements
were made in accordance to the European Thoracic So-
ciety standardization of lung volume measurements [8].
FEV1 %pred (forced expiratory volume in the 1st second
as % of predicted) and FVC %pred (forced vital capacity
as % of predicted), as well as TLC %pred (total lung cap-
acity as % of predicted), were calculated. All patients
underwent a skin prick testing with a standard panel of
airborne allergens (grasses, pellitory, ragweed, birch,
cypressus, olive, dermatophagoides pteronyssinus and far-
inae, cat and dog epithelia, alternaria tenuis, aspergillus
fumigatus). The test was considered positive if the mean
wheal diameter was 3 mm or larger after the subtraction
of the mean wheal of the negative control.
Periostin serum level analysis
Human periostin was dosed in serum samples. The assay
was performed by ELISA kit Human Periostin/OSF 2 of
Aviscera Bioscience. The kit contains the necessary com-
ponents required for the quantitative measurement of
recombinant and natural human periostin/OSF 2 in bio-
logical samples employing sandwich ELISA format. The
plate is pre-coated with antibody specific for Periostin
able to capture the periostin in the standard and the
samples. The periostin captured was detected by the
addition of a further periostin specific biotinylated anti-
body and streptavidin-HPR with its specific substrate. It
follows the emission of colorimetric signal directly pro-
portional to the concentration of periostin in the sample.
This signal was then measured by microplate spectro-
photometer at 450 nm. A standard curve was established
by plotting the log of the known concentrations of the
standard dilution (x axis) versus the log of this corre-
sponding O.D. (y-axis) and the log-log curve was gener-
ated for the calculation of periostin (ng/ml) in serum
samples. The detection limit of the ELISA assay used to
assess periostin levels was 2.0 ng/ml. The measurements
were performed blindly by one of the authors (MI), and
all investigators were never aware of the periostin levels
over the year of observation.
Statistical analysis
Statistical analysis was carried out using SPSS 21 and
GrapfPad Prism 6.0 for Windows. Normally distributed
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data are reported as mean ± standard deviation (SD) and
skewed data by median and range. Comparisons were
performer by parametric (Student’s t test) or non-
parametric (Mann-Whitney U tests) tests, as appropri-
ate. The relationships between variables are expressed as
Spearman’s rank correlation coefficient. For each test, a
p value of less than 0.05 was taken as the threshold of
statistical significance.
Results
A total of 15 moderate asthmatics (M/F: 10/5) were
studied. Patients had mean age of 47.6 ± 11.0 years, and
mean ACQ score of 5.5 ± 4.2. Lung function characteris-
tics of the study subjects are presented in Table 1. All
subjects were skin test positive to at least one aeroaller-
gen, and none was a current smoker (five subjects were
former smokers). In particular, 9 subjects were positive
to one aeroallergen (Dermatophagoides or Parietaria),
whereas the remaining 6 individuals showed multiple al-
lergen sensitizations.
At baseline, median values of serum periostin were
773 ng/ml (range: 28-4889 ng/ml). No statistically sig-
nificant correlations were detected between baseline
serum levels of periostin and lung function parameters;
similarly, serum periostin was not associated with the
ACQ score (p ≥0.05 for all analyses). Furthermore,
serum periostin levels did not show any association with
the allergic pattern (mono vs. polysensitized subjects) or
age at onset of asthma (data not shown). In the follow-
ing year, 5 subjects (33 % of the study group) reported
one or more asthma exacerbations (4 individuals with
one exacerbation and 1 individual with two exacerba-
tions), whereas the other 10 subjects did not experience
any exacerbation in the follow-up period. The levels of
periostin did not predict the time to the first exacerba-
tion, nor did they correlate with the rate of exacerba-
tions. All exacerbations were treated with a course of
oral corticosteroids, and disappeared within one week of
treatment, with no need to be admitted to hospital.
Baseline serum levels of periostin were significantly
higher in subjects who experienced one or more exacer-
bations during the follow-up, compared with those with
no exacerbations: median serum periostin levels were
4047.7 ng/ml (range: 2231.7 to 4889.0 ng/ml) and 222.0
ng/ml (range 28.2 to 1631.4 ng/ml), respectively; p =
0.001 (Fig. 1).
Discussion
The main finding of this explorative study is that serum
periostin concentrations are increased in moderate asth-
matics with unstable disease. Our observations advocate
for larger confirmatory studies whether serum periostin as
a predictive biomarker for greater risk of exacerbations.
The novelty of the current study is that high serum
periostin concentrations appears to predict acute asthma
exacerbations in the following year, providing evidence
for the potential association between persistent TH2- or
IL-13–driven inflammation and greater risk for loss of
asthma control. This is further emphasized by a recent
study by Song et al. [9], who showed a strong
Table 1 Demographic and lung function characteristics of the study subjects
# Gender Age Smoke FEV1% FVC% FEV1/FVC RV% TLC% RV/TLC% FRC%
1 F 37 n 108 133 70,6 83 116 72 92
2 M 64 n 109 102 78,2 88 93 90 85
3 M 33 n 77 78 79,4 79 77 99 54
4 M 44 f 91 105 70,4 77 96 79 70
5 F 55 n 83 112 63,3 86 97 86 112
6 M 35 f 54 88 49,6 96 90 108 93
7 M 31 f 73 95 61,4 99 96 102 97
8 F 44 n 107 130 71,1 106 118 91 83
9 M 48 n 62 87 55,5 138 101 127 112
10 M 61 n 61 76 61,2 107 86 126 84
11 F 41 f 86 91 81,9 96 90 106 75
12 F 46 n 110 108 88,1 98 100 99 77
13 M 62 f 100 94 81,2 88 89 94 81
14 M 58 n 59 95 48,0 148 114 135 116
15 M 55 n 49 73 52,3 114 86 129 108
Mean (SD) - 47.6 (11.0) - 81.9 (21.7) 97.8 (17.8) 67.5 (12.7) 100.2 (20.4) 96.6 (11.8) 102.9 (19.1) 89.3 (17.5)
Abbreviations: for Gender: M male, F female. For Smoke: f former smoker, n never smoker
FEV1%: forced expiratory volume at first second, % predicted, FVC%: forced vital capacity, % predicted, RV%: residual volume, % predicted, TLC%: total lung
capacity, % predicted, FRC%: functional residual capacity, % predicted
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relationship between serum concentrations of periostin
and airway hyperresponsiveness (AHR) to methacholine
and mannitol in asthmatic children. Moreover, Kene-
mitsu and colleagues [5] showed that, when patients
were stratified into two groups according to their serum
periostin levels, high serum periostin (≥95 ng/mL) was
also associated with greater decline in FEV1. Recently,
Nagasaki et al. [10] found that in patients with elevated
FeNO, the identification of high serum periostin levels
allowed to identify patients with faster FEV1 decline and
risk of asthma exacerbation, despite high doses of ICS.
These data are consistent with the notion that periostin
is a strong determinant of future risk in asthma. How-
ever, contradictory evidences exist: Gordon et al. [11] ex-
plored the biological role of periostin in asthma using a
mouse model and periostin deficient mice and, surpris-
ingly, found that periostin deficient mice have increased
AHR and markedly increased serum IgE levels following
repeated intranasal challenge with Aspergillus fumigatus
antigen, compared to wild-type mice controls. This led
the Authors to propose a protective role for epithelial
cell-derived periostin, probably mediated by TGF-beta-
induced differentiation of T regulatory cells.
Since ICS treatment reduces airway periostin expres-
sion [12] and airway eosinophilia [13], high levels of
serum periostin represent a marker of persistent airway
eosinophilia despite ICS treatment in patients with un-
controlled asthma [4]. It is possible to speculate that our
study subjects who experienced exacerbations were
among those in whom inhaled treatment did not sup-
press the eosinophilic inflammation. However, recent
evidence demonstrated that serum periostin is not able
to distinguish eosinophilic from non-eosinophilic airway
inflammation, whereas blood eosinophils had the highest
accuracy in the identification of sputum eosinophilia in
asthma [14]. The lack of measurements of sputum or
blood eosinophils in the current study limits any infer-
ence in this respect.
The present study has several limitations. Serum peri-
ostin was measured only once at enrollment, conse-
quently there are no data that may allow for the
assessment of intra-patient variability. However, low
intra-patient variability for serum periostin has been
already demonstrated [6]. The small number of recruited
subjects may have affected the findings of the study. Due
to the explorative nature of this study, results need to be
confirmed in a larger sample of patients; however, the
prospective nature and the design of the present study
allowed a precise collection of each exacerbation event,
thus providing reliable data for the analysis. Finally, the
apparent discrepancy of the levels of serum periostin be-
tween the current study and other observations can be
likely attributed to the different methodologies used. Al-
though much higher than those measured elsewhere, the
periostin levels were still able to discriminate between
subjects with recurrent exacerbations and those in stable
conditions.
Conclusions
In conclusion, periostin could be envision as a novel bio-
marker to better characterize asthmatic subjects with
higher risk of exacerbations. The findings of the present
pilot study could form the basis for the design of larger
studies aiming at developing strategies to identify pa-
tients at risk for exacerbations.
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